An increasing number of polypeptide growth factors and cytokines are now known to bind to heparin and heparan sulphate glycosaminoglycans. Well studied examples are members of the chemokine and fibroblast growth factor families. However other growth factors including proinflammatory and haematopoietic cytokmes also bind to heparin [ 1-41, Such interaction with glycosaminoglycans of the extracellular matrix and cell surface may be important in protecting cytokines against degradation, and in localising them close to their sites of secretion.
value of around 50Ong/ml. With AT III, we have found that an AT 111-binding heparin fiaction separated by aflimty chromatography on immobilised AT 111, is a strong competitor in our ELISA. Conversely the low affinity heparin fraction is a poor competitor. Thus our ELISA shows the anticipated specificity in heparin-protein interactions.
We have now shown that recombinant human i n t e r l e h 2, rIL-2, binds to the heparin complex (see Fig 1) . The binding is dose dependent, but over a range of 0-100ng does not reach saturation. As with AT 111 and FGF-2, free heparin displaces rIL-2 fiom the complex, but with rIL-2 the EC,, for mhibition of binding is an order of magnitude higher, at around 7pg/ml. Thus it would appear that the afhuty of IL-2 for heparin is lower than that of AT 111 and By using various polysaccharides to compete with the immobilised heparin-BSA complex for binding to rIL-2, we are able to examine the specificity of the interaction. Thus far we have found that chondroitin sulphate fails to compete, whereas fucoidin competes strongly. These results therefore confirm and extend previous affinity chromatography studies which showed that rIL-2 binds fucoidin and heparin but not chondroitin sulphate [3] .
T h s binding of IL-2 to heparin-like glycosaminoglycans is llkely to maintain high concentrations of the cytolune at local tissue sites of release, thus enabling a paracrine mode FGF-2. of immune activation in vivo. Such localisation should be considered in the therapeutic exploitation of recombinant IL-2 in order to minimise the toxic effects which occur on systemic admuustration.
